IDiyas

For the Inventor, By the Inventor

Hightstown, NJ, United States of America

David J Diller

USPTO Granted Patents = 15 

 

Average Co-Inventor Count = 7.0

ph-index = 5

Forward Citations = 85(Granted Patents)


Location History:

  • Hightstown, NJ (US) (2007 - 2011)
  • East Windsor, NJ (US) (2006 - 2024)

Company Filing History:

goldMedal5 out of 134 
 
Ligand Pharmaceuticals, Inc.
 patents
silverMedal4 out of 101 
 
Pharmacopeia Inc.
 patents
bronzeMedal3 out of 8 
 
Venenum Biodesign, LLC
 patents
4. 2 out of 1,309 
 
Wyeth
 patents
5. 2 out of 3,681 
 
Bristol-myers Squibb Compnay
 patents
6. 1 out of 8 
 
Accelrys Software, Inc.
 patents
where one patent can have more than one assignee

Years Active: 2006-2024

Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents
1. 11883420 - Sting agonists for treating bladder cancer and solid tumors (2024-01-30),
2. 11773110 - Heterocycle amines and uses thereof (2023-10-03),
3. 11186593 - Heterocycle amines and uses thereof (2021-11-30),
4. 11161864 - Sting agonists (2021-11-02),
5. 11110106 - Sting agonists for treating bladder cancer and solid tumors (2021-09-07),
6. 10604533 - Heterocycle amines and uses thereof (2020-03-31),
7. 10030034 - Heterocycle amines and uses thereof (2018-07-24),
8. 9266874 - Heterocycle amines and uses thereof (2016-02-23),
9. 8044040 - N-heterocyclic inhibitors of TNF-alpha expression (2011-10-25),
10. 7989459 - Purinones and 1H-imidazopyridinones as PKC-theta inhibitors (2011-08-02),
11. 7951803 - 8-heteroarylpurine MNK2 inhibitors for treating metabolic disorders (2011-05-31),
12. 7919490 - 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression (2011-04-05),
13. 7902187 - 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression (2011-03-08),
14. 7253174 - N-heterocyclic inhibitors of TNF-α expression (2007-08-07),
15. 7065453 - Molecular docking technique for screening of combinatorial libraries (2006-06-20),

Title: An Overview of Inventor David J Diller

Introduction

David J Diller, an accomplished inventor based in Hightstown, NJ, holds an impressive portfolio of 15 patents. His innovative contributions largely focus on advancements in medical treatments, particularly for cancer and inflammatory disorders.

Latest Patents

One of David's notable patents is for sting agonists aimed at treating bladder cancer and solid tumors. This patent details methods for administering a specific compound to patients, which represents a significant step forward in cancer treatment. Another recent patent involves heterocycle amines, where David discloses various compounds and methods that have applications in chemistry and medicine. Some of these embodiments highlight the effectiveness of heterocycle amines in treating inflammatory disorders.

Career Highlights

Throughout his career, David has been associated with prominent companies in the pharmaceutical industry, including Ligand Pharmaceuticals, Inc. and Pharmacopeia Inc. His work in these organizations has contributed to the development of effective treatment options and has solidified his reputation as a key innovator in his field.

Collaborations

David has collaborated with notable individuals such as Brian F McGuinness and Axel Metzger. These collaborations have enabled the exchange of ideas and the enhancement of research in innovative medical treatments.

Conclusion

David J Diller's dedication to innovation has produced a series of valuable patents that advance the fields of medicine and chemistry. His contributions are helping to shape the future of treatment methodologies, particularly in the fight against cancer and inflammatory disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…